Dupixent® (Dupilumab) Is Approved for the Treatment of Moderate-to-Severe Atopic Dermatitis in Children 6 Months to 5 Years

The Asthma and Allergy Foundation of America (AAFA) is sharing this press release from Regeneron Pharmaceuticals, Inc. and Sanofi to bring you the latest research news. [PRESS RELEASE] FDA Approves Dupixent® (Dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significantly improved overall disease severity and significantly…

Lesen Sie weiter auf: Dupixent® (Dupilumab) Is Approved for the Treatment of Moderate-to-Severe Atopic Dermatitis in Children 6 Months to 5 Years
Quelle: Asthma and Allergy Foundation of America
Titelbild/Grafik by Asthma and Allergy Foundation of America (AAFA)

Kommentare und Fragen

Möchten Sie zu diesem Artikel ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!

Weiteres von Asthma and Allergy Foundation of America

• Learn About Asthma in Infants and Young Children
• FDA Authorizes COVID-19 Vaccines for Children 6 Months and Older
• Find Out If Your Home Is Asthma and Allergy Friendly With Our Healthier Home Assessment
• Dupixent® (Dupilumab) Is Approved for the Treatment of Moderate-to-Severe Atopic Dermatitis in Children 6 Months to 5 Years
• Fun Ways to Teach Children About Asthma
• AAFA Marks Day of Remembrance for Lives Lost to Asthma and Allergies
• How to Avoid Allergy and Asthma Triggers During Outdoor Parties and Cookouts
• Understanding Eosinophilic Asthma
• Tips on How to Use Your Inhaler to Get More Medicine Into Your Lungs for Better Asthma Control
• Advocacy Action Day for People With Asthma and Allergies